IRD

#3307
Opus Genetics, Inc. - Common Stock
3.6 9 USD
-0.04%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.69
3.69
Intervallo Annuale
2.82
5.81
Variazione giornaliera
-4.16%
Variazione Mensile
-4.16%
Variazione di 6 mesi
-9.56%
Variazione Annuale
-0.81%
Chiusura Precedente
3.8 5
Open
3.6 9
Minimo
3.6 9
Massimo
3.6 9
Volume
59
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, Q3 FY2025

Full document

Opus Genetics, Inc. Form 8-K Summary

Business Context and Reporting Period

Opus Genetics, Inc. (Nasdaq: IRD), a Delaware corporation, filed this Current Report on Form 8-K on August 25, 2025. The filing discloses the completion of a private placement of equity securities.

Key Financial Metrics

  • Capital Raised: Approximately $3.5 million in aggregate gross proceeds.
  • Shares Issued: 3,138,338 shares of common stock.
  • Transaction Costs: No underwriting discounts or commissions were paid.
  • Liquidity Impact: The filing does not provide specific pre-transaction cash balances or debt levels; however, the proceeds are intended to bolster liquidity for operational needs.

Material Changes

The primary material change is the increase in equity capital and outstanding share count resulting from the private placement closed on August 25, 2025. The transaction was led by Cam Gallagher, Chair of the Board, who invested $1.0 million, alongside participation from lead independent director Sean Ainsworth and other investors.

Outlook, Management Commentary, and Risks

Use of Proceeds: Management intends to use net proceeds to expedite manufacturing process development, including the scale-up of clinical and commercial production and testing. The goal is to ensure sufficient supply of cGMP material for gene therapy candidates OPGx-LCA5 and OPGx-BEST1.

Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include uncertainties related to market conditions, the satisfaction of closing conditions, general economic conditions, and the ability to successfully scale manufacturing as planned. The company notes that actual results may differ materially from expectations.

Investor Verification Checklist

  • Verify the exact number of shares issued (3,138,338) and the resulting dilution impact on existing shareholders.
  • Confirm the specific terms of the subscription agreements, including any registration rights or vesting schedules not detailed in the 8-K.
  • Review the company's most recent Form 10-K or 10-Q to assess current cash runway and burn rate relative to the $3.5 million raised.
  • Monitor subsequent filings for updates on the manufacturing scale-up progress for OPGx-LCA5 and OPGx-BEST1.